ShareInvestor.com

Latest News

• 14 Nov 2019 19:20
  QT Vascular: Financial Statements and Related Announcement :: Third Quarter Results Source: SGXNet
• 13 Aug 2019 18:47
  QT Vascular: Financial Statements and Related Announcement :: Second Quarter and/ or Half Yearly Results Source: SGXNet
• 06 Aug 2019 09:00
  Director activity subsides as earnings take centre stage Source: Business Times
• 01 Aug 2019 12:12
  QT Vascular: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s) :: Change in Interest of Substantial Shareholder Source: SGXNet
• 25 Jun 2019 10:29
  QT Vascular: Paclitaxel-Coated Devices Should Remain On The Market. Source: ShareInvestor Express
• 24 Jun 2019 20:28
  QT Vascular: General Announcement :: Media Release - Update on FDA Panel Meeting on Paclitaxel Coated Products Source: SGXNet
• 14 Jun 2019 20:53
  QT Vascular: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s) :: Notification in respect of becoming a Substantial Shareholder Source: SGXNet
• 14 Jun 2019 20:52
  QT Vascular: General Announcement :: Issuance of 142,639,054 New Ordinary Shares Pursuant to the Loan Extension Deed Dated 15 May 2019 Source: SGXNet

Key Statistics

Notes:

1. Based on latest Full Year results announcement, adjusted for the current number of shares.
2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
3. Rounded to the nearest thousand. Updated on 21 Nov 2019.Please click here for more information.
4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
6. Based on Trailing EPS.
7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
8. Rounded to the nearest thousand.
9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Total Shareholder Return

Notes:

1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
2. Script dividends are ignored in this calculation.

Price Movements

Notes:

1. Price movements are based on adjusted historical data.

Company Background

The Group is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The Group collaborates with industry specialists and physicians who are key opinion leaders to develop and offer physicians and patients new and differentiated devices to improve outcomes in complex peripheral and coronary interventions.

IPO Performance

More Information Available

More information is available to our subscribers, including:

• Market Moving News from Dow Jones Newswires
• Consensus Estimates
• Dividend/Distribution History
• Financial Summary with Financial Period Comparison
• Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
• Events Calendar for Results Announcements, Ex-Dates etc
• Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.